Johnson & Johnson Pulls Health Care Lower as Heavyweights Lag

The Health Care sector fell under pressure from its largest holdings on Tuesday, October 13, with the exchange-traded fund Health Care Select Sector SPDR Fund (XLV) closing -1.3%. While 53.0% of the fund's graded weight carries top quality grades of A or B, sector breadth was narrow, with 41.4% of its members advancing. The sector's largest constituents drove the pullback, creating a clear gap between market-cap weighting and the average stock: the cap-weighted sector finished -1.2%, while an equal-weighted measure was -0.4%. That drag centered on Johnson & Johnson, which finished -5.7% after reporting a $5.5 billion litigation charge tied to talc settlements that compressed quarterly net profit.

The talc litigation expense overshadowed an operational quarter in which the company raised its full-year guidance, pulling GAAP earnings down to $0.09 per share compared with $2.12 a year earlier. Investors also reacted to underperformance in the medical technology segment. Legal settlement headlines extended to pharmacy distribution as well, with CVS Pharmacy agreeing to a $315 million settlement with the Justice Department over opioid prescription dispensing practices.

Gains within the sector were led by Centene Corp, which closed +2.8%, while Mettler-Toledo International Inc finished +2.3%. The milder drop in the equal-weighted sector demonstrates that selling was not uniform across the board. Across the wider market, 4 of the 11 sectors rose on the day, leaving health care among the session's laggards.

Investors using XLV pay an expense ratio of 0.08% to access the broad sector, yet the fund's cap-weighted structure leaves performance tightly tethered to its largest names rather than the broader field. Over longer horizons, the sector remains firmly positive, with the fund recording +19.6% over the past twelve months. The session's pullback highlights how single-company developments among mega-caps can exert outsized influence over broader index performance.